FM
fazen.markets
healthcare·esfritzh

Interpace Biosciences Q3 Revenue Jumps 18% to $10.4M

0h ago|5 min readStandard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

interpace-biosciencesidxg-stockmolecular-diagnosticsthyroid-testingq3-2026-earnings
Sponsoredby Fazen Capital

AiX — Free Expert Advisor

Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.

Myfxbook verified No subscription XAUUSD M15
Get Free EA

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.

Key Takeaways

  • 1Interpace completed its exit from pancreatic testing in May 2025, when it discontinued the PancraGEN business, and now operates as a thyroid-only molecular diagnostics company.
  • 2The headline figures sit alongside a mixed bottom line.
  • 3The report's central tension is that revenue growth and margin expansion are running alongside a GAAP loss.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Interpace Biosciences, Inc. (OTCID: IDXG) reported third-quarter 2026 revenue of $10.4 million on 16 November 2026, an 18% increase from $8.8 million in the prior-year quarter, while swinging to a loss from continuing operations of $1.5 million from income of $1.0 million a year earlier. The Parsippany, New Jersey-based thyroid-only molecular diagnostics company said the loss included roughly $4.1 million of non-recurring stock compensation costs and non-recurring legal expenses. Adjusted EBITDA rose to $2.1 million, or 20% of revenue, from $1.3 million.

Context — why Interpace's Q3 2026 results matter now

Interpace completed its exit from pancreatic testing in May 2025, when it discontinued the PancraGEN business, and now operates as a thyroid-only molecular diagnostics company. That structural change makes the prior-year comparatives messy: reported 2025 figures still include PancraGEN revenue and related costs, while current-year results do not. Starting with the third quarter of 2026, the company said reported year-over-year comparisons are presented on a directly comparable thyroid-only basis, because the prior-year periods no longer include PancraGEN.

The company also disclosed a one-for-five reverse stock split effected on 27 August 2026. All share and per-share figures in the release give effect to that split, which is why the weighted average basic share count jumped to 5,705 thousand in Q3 2026 from 885 thousand a year earlier.

Management framed the quarter as evidence that the post-transition business is durable. Chief Financial Officer Chris McCarthy said the company continued to convert revenue growth into margin expansion, describing operating use built into the business. President and CEO Tom Burnell said the third quarter demonstrated the durability of the business built through last year's transition and the operating discipline the company will carry through the remainder of 2026 and into 2027.

Gross margin expanded to 69% in Q3 2026 from 62% a year earlier and 63% on a pro forma basis, supported by an 11% increase in average thyroid revenue per test and efficiency gains in the laboratory. Adjusted EBITDA margin improved to 20% from 14% in the prior-year quarter and 17% on a pro forma basis.

The macro backdrop is not cited in the report, and the company did not disclose any interest-rate or reimbursement-policy sensitivity tied to the quarter.

Data — what the numbers show

The headline figures sit alongside a mixed bottom line. Revenue of $10.4 million, or $10,373 thousand, compared with $8,756 thousand a year earlier. Gross profit rose to $7,180 thousand from $5,439 thousand, with cost of revenue falling to $3,193 thousand from $3,317 thousand. Operating expenses, however, climbed to $9,580 thousand from $4,294 thousand, driven by general and administrative costs of $6,716 thousand versus $2,057 thousand, reflecting the non-recurring charges.

MetricQ3 2026Q3 2025
Revenue$10.4M$8.8M
Gross margin69%62%
Operating (loss) income$(2.4)M$1.1M
Adjusted EBITDA$2.1M$1.3M
Cash collections$9.1M$10.0M

Year-to-date revenue for the nine months ended 30 September 2026 was $28.5 million, down from $29.5 million as reported but up 13% from $25.3 million on a pro forma basis that excludes PancraGEN. Nine-month gross margin was 66%, compared with 61% as reported and 59% pro forma. Adjusted EBITDA for the period was $4.4 million, or 15% of revenue, versus $3.7 million and 13% as reported and $2.5 million and 10% pro forma.

On a trailing twelve-month basis, thyroid revenue reached $38.0 million, up about 13% over the comparable prior twelve-month period pro forma, on thyroid test volume growth of roughly 9%. Q3 thyroid volume rose 7% year over year and thyroid revenue rose 18%. Cash and cash equivalents stood at $2,929 thousand at 30 September 2026, up from $2,505 thousand at 31 December 2025. Total stockholders' equity was $24,691 thousand.

Analysis — what it means for diagnostics markets and IDXG

The report's central tension is that revenue growth and margin expansion are running alongside a GAAP loss. The $4.1 million of non-recurring stock compensation and legal costs is larger than the $1.5 million loss itself, meaning the underlying thyroid business generated positive Adjusted EBITDA of $2.1 million. Investors comparing Interpace against larger molecular diagnostics names should note that the company's entire revenue base is now one clinical franchise, ThyGeNEXT and ThyraMIR v2, with no diversification from pancreatic testing after the May 2025 discontinuation.

That concentration cuts both ways. The 11% increase in average thyroid revenue per test and the 7% volume gain show pricing and utilization both moving in the right direction, but a single reimbursement or competitive shock to thyroid nodule testing would hit the whole revenue line. The report does not name any competitors, and no peer figures are supplied, so no relative valuation claim can be made from the disclosed data.

The pancreatic cancer program is the second-order story. Interpace said it is seeking to extend the next-generation sequencing and microRNA platforms behind ThyGeNEXT and ThyraMIR v2 into pancreatic cancer, with a genomic panel and proprietary microRNA classification aligned with National Comprehensive Cancer Network guidelines. Analytical validation is underway, with clinical validation and utility studies planned across 2026 and 2027. The company explicitly said the product is in development, not cleared or approved by the FDA, and does not expect it to contribute revenue in 2026 or 2027.

The acknowledged limitation is cash conversion: Q3 cash collections of $9.1 million came in below the prior-year quarter's $10.0 million even as revenue rose, and nine-month net cash provided by operating activities fell to $1,351 thousand from $3,693 thousand. Revenue recognition at the company is based in part on estimates for future collections, which the report flags as a risk factor. Positioning is difficult to infer because the report discloses no institutional ownership or short interest data.

Outlook — what to watch next

The report gives no calendar dates for the pancreatic program beyond analytical validation underway and clinical validation and utility studies planned across 2026 and 2027, with reimbursement and launch activities to follow. Investors should treat any program update as the primary catalyst, alongside the company's next quarterly filing.

Margin trajectory is the second watch item. Management said it expects scaling operating use in line with volume growth without a corresponding increase in headcount to support continued margin expansion. Year-to-date gross margin of 66% and Adjusted EBITDA margin of 15% are the reference points against which the next quarter will be measured.

The company said its debt-free balance sheet supports investment in laboratory automation, AI-enabled productivity initiatives, and research and development. Average ThyGeNEXT and ThyraMIR v2 turnaround time improved approximately 11% in the first nine months of 2026 versus the prior-year period, a metric worth tracking as a proxy for laboratory efficiency. The report names no support or resistance levels and no price targets.

Frequently Asked Questions

Why did Interpace Biosciences report a loss when revenue grew 18%?

The loss from continuing operations of $1.5 million included approximately $4.1 million of non-recurring stock compensation costs and non-recurring legal expenses, which the company excludes from Adjusted EBITDA. Those charges pushed general and administrative expenses to $6,716 thousand from $2,057 thousand a year earlier. Stripping them out, Adjusted EBITDA was positive at $2.1 million, or 20% of revenue.

What is Interpace's pancreatic cancer program status?

Interpace said analytical validation of its pancreatic panel design is underway, with clinical validation and utility studies planned across 2026 and 2027, followed by reimbursement and launch activities. The product is in development, not available for clinical use, and has not been cleared or approved by the FDA. The company does not expect the program to contribute revenue in 2026 or 2027.

Sponsored — AiX

Trade XAUUSD on autopilot — free Expert Advisor

AiX is our free MetaTrader 5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.

Get Free EA

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related